Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3170

1.

Translating the anti-myeloma activity of Natural Killer cells into clinical application.

Fionda C, Stabile H, Molfetta R, Soriani A, Bernardini G, Zingoni A, Gismondi A, Paolini R, Cippitelli M, Santoni A.

Cancer Treat Rev. 2018 Nov;70:255-264. doi: 10.1016/j.ctrv.2018.10.005. Epub 2018 Oct 10. Review.

PMID:
30326421
2.

Drug resistance in multiple myeloma.

Robak P, Drozdz I, Szemraj J, Robak T.

Cancer Treat Rev. 2018 Nov;70:199-208. doi: 10.1016/j.ctrv.2018.09.001. Epub 2018 Sep 4. Review.

PMID:
30245231
3.

Value and Cost of Myeloma Therapy.

Rajkumar SV.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):662-666. doi: 10.1200/EDBK_200867. Review.

4.

Bones in Multiple Myeloma: Imaging and Therapy.

Zamagni E, Cavo M, Fakhri B, Vij R, Roodman D.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):638-646. doi: 10.1200/EDBK_205583. Review.

5.

CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.

Cohen AD.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):e6-e15. doi: 10.1200/EDBK_200889. Review.

6.

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside.

Perrot A, Corre J, Avet-Loiseau H.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):675-680. doi: 10.1200/EDBK_200879. Review.

7.

Value and Cost of Myeloma Therapy-We Can Afford It.

Fonseca R, Hinkel J.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):647-655. doi: 10.1200/EDBK_200869. Review.

8.

Global Approaches in Myeloma: Critical Trials That May Change Practice.

Moreau P, Touzeau C.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):656-661. doi: 10.1200/EDBK_200841. Review.

9.

Practical Considerations for Antibodies in Myeloma.

Laubach JP, van de Donk N, Davies FE, Mikhael J.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):667-674. doi: 10.1200/EDBK_205443. Review.

10.

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.

Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, Evangelista A, Di Renzo N, Musto P, Marcatti M, Vallone R, Storti S, Bernardini A, Centurioni R, Aitini E, Palmas A, Annibali O, Angelucci E, Ferrando P, Baraldi A, Rocco S, Andriani A, Siniscalchi A, De Stefano V, Meneghini V, Palumbo A, Grammatico S, Boccadoro M, Larocca A.

Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18. Review.

PMID:
30196909
11.

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.

Gandolfi S, Vekstein C, Laubach JP, O'Brien A, Masone K, Munshi NC, Anderson KC, Richardson PG.

Clin Adv Hematol Oncol. 2018 Aug;16(8):564-574. Review.

PMID:
30148829
12.

The safety of bortezomib for the treatment of multiple myeloma.

Cengiz Seval G, Beksac M.

Expert Opin Drug Saf. 2018 Sep;17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30. Review.

PMID:
30118610
13.

Proteasome inhibitors for multiple myeloma.

Okazuka K, Ishida T.

Jpn J Clin Oncol. 2018 Sep 1;48(9):785-793. doi: 10.1093/jjco/hyy108. Review.

PMID:
30102324
14.

Myeloma patients' experiences of haematopoietic stem cell transplant: A qualitative thematic synthesis.

Walpole G, Clark H, Dowling M.

Eur J Oncol Nurs. 2018 Aug;35:15-21. doi: 10.1016/j.ejon.2018.05.002. Epub 2018 May 15. Review.

PMID:
30057079
15.
16.

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.

Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, Vranic S.

Int J Mol Sci. 2018 Jul 18;19(7). pii: E2087. doi: 10.3390/ijms19072087. Review.

17.

New Insights in Anti-Angiogenesis in Multiple Myeloma.

Ribatti D, Vacca A.

Int J Mol Sci. 2018 Jul 12;19(7). pii: E2031. doi: 10.3390/ijms19072031. Review.

18.

Spinal metastases in multiple myeloma: A high-risk subgroup for ISS III patients.

Cossu G, Terrier LM, Benboubker L, Destrieux C, Velut S, Fran├žois P, Zemmoura I, Amelot A.

Surg Oncol. 2018 Jun;27(2):321-326. doi: 10.1016/j.suronc.2018.05.005. Epub 2018 May 3. Review.

PMID:
29937188
19.

Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma.

Luczkowska K, Litwinska Z, Paczkowska E, Machalinski B.

J Physiol Pharmacol. 2018 Apr;69(2). doi: 10.26402/jpp.2018.2.02. Epub 2018 Jun 13. Review.

20.

An atypical presentation of POEMS syndrome with IgG kappa type M protein and normal VEGF level: Case report and review of literature.

Pulivarthi S, Gurram MK.

J Cancer Res Ther. 2018 Apr-Jun;14(3):679-681. doi: 10.4103/0973-1482.172123. Review.

Supplemental Content

Loading ...
Support Center